US2012115205A1PendingUtilityA1

Botulinum Neurotoxin Serotype B Activatable Botulinum Neurotoxin Serotype Bs

50
Assignee: STEWARD LANCE EPriority: Sep 19, 2005Filed: Aug 30, 2010Published: May 10, 2012
Est. expirySep 19, 2025(expired)· nominal 20-yr term from priority
A61P 9/02A61P 5/00A61P 35/00A61P 27/16A61P 27/02A61P 25/00A61P 29/00A61P 21/00C07K 14/33A61P 17/00
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The specification discloses modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located in the di-chain loop region; and method of producing modified Clostridial toxins comprising Clostridial toxin substrate cleavage site located within the di-chain loop region.

Claims

exact text as granted — not AI-modified
1 . A recombinantly modified BoNT/A comprising an enzymatic domain having a zinc-dependent endopeptidase activity which targets a synaptosomal-associated protein of 25 kDa (SNAP-25), a translocation domain, a binding domain and a modified di-chain loop region, the modified di-chain loop region intervening between the enzymatic domain and the translocation domain;
 wherein the di-chain loop region modification comprises a BoNT/A substrate cleavage site from a SNAP-25 of at least six amino acids in length located within the di-chain loop region that is proteolytically cleaved by the enzymatic domain of the recombinantly modified BoNT/A; and   wherein expression of the recombinantly modified BoNT/A within a cell results in single chain to di-chain conversion of the recombinantly modified BoNT/A due to proteolytic cleavage of the BoNT/A substrate cleavage site.   
     
     
         2 .- 9 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.